Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

G5166

Sigma-Aldrich

PNGase F from Elizabethkingia miricola

buffered aqueous solution

Sign Into View Organizational & Contract Pricing

Synonym(s):
N-Glycosidase F, Peptide N-glycosidase
CAS Number:
Enzyme Commission number:
MDL number:
UNSPSC Code:
12352204
NACRES:
NA.32

biological source

bacterial (Elizabethkingia miricola)

Quality Level

conjugate

(N-linked)

form

buffered aqueous solution

specific activity

≥20000 units/mg protein

mol wt

36 kDa

shipped in

wet ice

storage temp.

2-8°C

General description

PNGase F (Peptide N-glycosidase F) cleaves asparagine-linked glycoproteins, which produces carbohydrate-free peptides and detached full-length oligosaccharides.

Application

PNGase F from Elizabethkingia miricola has been used for the deglycosylation of the proteins.
Used to deglycosylate protein.

Biochem/physiol Actions

Cleaves an entire glycan from a glycoprotein provided the glycosylated asparagine moiety is substituted on its amino and carboxyl terminus with a polypeptide chain.

Unit Definition

One unit will catalyze the release of N-linked oligosaccharides from 1 nanomole of denatured ribonuclease B in one minute at 37°C at pH 7.5 monitored by SDS-PAGE. One Sigma unit of PNGase F activity is equal to 1 IUB milliunit.

Physical form

Supplied as a solution in 20 mM Tris HCl, pH 7.5, 50 mM NaCl and 1 mM EDTA

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Precautionary Statements

Hazard Classifications

Resp. Sens. 1

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

常规特殊物品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ying-Nai Wang et al.
STAR protocols, 3(1), 101198-101198 (2022-03-05)
Immunotherapy via PD-1/PD-L1 blockade is a promising strategy to eradicate cancer cells. However, the PD-L1 pathological level is inconsistent with the therapeutic response and is not a reliable biomarker to stratify patients for anti-PD-1/PD-L1 therapy. Here, we describe patient sample deglycosylation
A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor
Jun LS, et al.
PLoS ONE, 9(4), e93746-e93746 (2014)
Identification and Characterization of a Novel Prokaryotic Peptide N-GLYCOSIDASE FROM ELIZABETHKINGIA MENINGOSEPTICA
Sun G, et al.
The Journal of Biological Chemistry, 290(12), 7452-7462 (2015)
Lucy S Jun et al.
PloS one, 9(4), e93746-e93746 (2014-04-04)
Class B G protein-coupled receptors (GPCRs) are important regulators of endocrine physiology, and peptide-based therapeutics targeting some of these receptors have proven effective at treating disorders such as hypercalcemia, osteoporosis, and type 2 diabetes mellitus (T2DM). As next generation efforts
Gabor Keresztes et al.
Vaccines, 10(2) (2022-02-27)
(1) Influenza viruses constantly change and evade prior immune responses, forcing seasonal re-vaccinations with updated vaccines. Current FDA-approved vaccine manufacturing technologies are too slow and/or expensive to quickly adapt to mid-season changes in the virus or to the emergence of

Articles

Explore strategies for releasing N-linked glycans with PNGase F, PNGase A & native & sequential deglycosylation with endoglycosidases & exoglycosidases.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service